Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. (EGX: RMDA)
Egypt
· Delayed Price · Currency is EGP 3.660
0.00 (0.00%)
At close: Oct 15, 2024
RMDA Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 2,101 | 1,922 | 1,484 | 1,246 | 960.17 | 893.97 | Upgrade
|
| Revenue Growth (YoY) | 30.11% | 29.54% | 19.06% | 29.81% | 7.41% | 10.98% | Upgrade
|
| Cost of Revenue | 1,116 | 1,018 | 765.28 | 669.61 | 514.34 | 488.92 | Upgrade
|
| Gross Profit | 985.45 | 904.06 | 718.67 | 576.82 | 445.83 | 405.04 | Upgrade
|
| Selling, General & Admin | 503.23 | 444.06 | 360.96 | 303.18 | 258.18 | 187.75 | Upgrade
|
| Other Operating Expenses | -8.79 | -7.34 | -6.04 | -0.76 | -1.16 | -2.01 | Upgrade
|
| Operating Expenses | 508.04 | 458.3 | 376.41 | 302.53 | 258.82 | 187.03 | Upgrade
|
| Operating Income | 477.41 | 445.76 | 342.26 | 274.29 | 187.01 | 218.01 | Upgrade
|
| Interest Expense | -253.05 | -191.2 | -89.07 | -91.03 | -96.64 | -105.8 | Upgrade
|
| Interest & Investment Income | 66.72 | 62.9 | 56.73 | 59.97 | 64.16 | 4.65 | Upgrade
|
| Currency Exchange Gain (Loss) | 52.22 | 18.68 | 25.65 | -0.6 | -1.7 | -2.18 | Upgrade
|
| Other Non Operating Income (Expenses) | -10 | -8.84 | -6.99 | -8.31 | -7.58 | -7.5 | Upgrade
|
| EBT Excluding Unusual Items | 333.31 | 327.31 | 328.58 | 234.33 | 145.25 | 107.18 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.14 | 0.14 | -0.13 | -0.72 | -0.14 | 0.01 | Upgrade
|
| Pretax Income | 333.45 | 327.45 | 328.45 | 233.61 | 145.11 | 107.19 | Upgrade
|
| Income Tax Expense | 75.64 | 74.24 | 75.57 | 53.52 | 33.59 | 25.51 | Upgrade
|
| Earnings From Continuing Operations | 257.8 | 253.21 | 252.89 | 180.09 | 111.51 | 81.68 | Upgrade
|
| Minority Interest in Earnings | -9.77 | -8.35 | -7.21 | 1 | 0.67 | 0.71 | Upgrade
|
| Net Income | 248.03 | 244.86 | 245.68 | 181.09 | 112.18 | 82.39 | Upgrade
|
| Preferred Dividends & Other Adjustments | 21.36 | 21.36 | 16.76 | 14.7 | 14.7 | - | Upgrade
|
| Net Income to Common | 226.67 | 223.5 | 228.91 | 166.39 | 97.48 | 82.39 | Upgrade
|
| Net Income Growth | 4.59% | -0.33% | 35.67% | 61.43% | 36.15% | -36.14% | Upgrade
|
| Shares Outstanding (Basic) | 1,491 | 1,491 | 1,475 | 1,523 | 1,523 | 1,523 | Upgrade
|
| Shares Outstanding (Diluted) | 1,496 | 1,501 | 1,483 | 1,523 | 1,523 | 1,523 | Upgrade
|
| Shares Change (YoY) | 1.53% | 1.27% | -2.62% | - | 0.00% | 17.52% | Upgrade
|
| EPS (Basic) | 0.15 | 0.15 | 0.16 | 0.11 | 0.06 | 0.05 | Upgrade
|
| EPS (Diluted) | 0.15 | 0.15 | 0.15 | 0.11 | 0.06 | 0.05 | Upgrade
|
| EPS Growth | 1.42% | -3.56% | 41.28% | 70.69% | 18.31% | -45.66% | Upgrade
|
| Free Cash Flow | -110.58 | -135.54 | -5.03 | 188.68 | -249.31 | -28.44 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.09 | -0.00 | 0.12 | -0.16 | -0.02 | Upgrade
|
| Dividend Per Share | 0.067 | 0.067 | - | - | - | - | Upgrade
|
| Gross Margin | 46.90% | 47.03% | 48.43% | 46.28% | 46.43% | 45.31% | Upgrade
|
| Operating Margin | 22.72% | 23.19% | 23.06% | 22.01% | 19.48% | 24.39% | Upgrade
|
| Profit Margin | 10.79% | 11.63% | 15.43% | 13.35% | 10.15% | 9.22% | Upgrade
|
| Free Cash Flow Margin | -5.26% | -7.05% | -0.34% | 15.14% | -25.97% | -3.18% | Upgrade
|
| EBITDA | 550.66 | 514.61 | 403.67 | 316.61 | 239.55 | 254.27 | Upgrade
|
| EBITDA Margin | 26.21% | 26.77% | 27.20% | 25.40% | 24.95% | 28.44% | Upgrade
|
| D&A For EBITDA | 73.25 | 68.85 | 61.41 | 42.31 | 52.54 | 36.25 | Upgrade
|
| EBIT | 477.41 | 445.76 | 342.26 | 274.29 | 187.01 | 218.01 | Upgrade
|
| EBIT Margin | 22.72% | 23.19% | 23.06% | 22.01% | 19.48% | 24.39% | Upgrade
|
| Effective Tax Rate | 22.69% | 22.67% | 23.01% | 22.91% | 23.15% | 23.80% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.